Cell Death News and Research

RSS

Absence of Puma and Bim protein leads to autoimmune diseases

Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs.

7 Sep 2012

New cell screening method can identify potential anti-influenza drugs

Medical Systems Virology group at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, together with its national and international collaborators, developed a new cell screening method that can be used to identify potential anti-influenza drugs.

6 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012

CNIO team generates transgenic mouse model for aplastic anaemia associated with short telomeres

Aplastic anaemia is characterised by a reduction in the number of the bone marrow cells that go on to form the different cell types present in blood (essentially red blood cells, white blood cells and platelets). In most cases, the causes of the disorder are hard to determine, but some patients have been found to have genetic alterations leading to a shortening of their telomeres (the end regions of chromosomes that protect and stabilise DNA).

30 Aug 2012

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012.

29 Aug 2012

Study shows molecular mechanism behind type 3c pancreatic diabetes

Mice develop pancreatic diabetes (type 3c) when they lack certain genes in the E2F group, and to understand how this happens, Olatz Zenarruzabeitia has focussed on the molecular mechanism behind it.

29 Aug 2012

Control of siRNA could aid regenerative medicine, cancer therapy

Some of the body's own genetic material, known as small interfering RNA (siRNA), can be packaged then unleashed as a precise and persistent technology to guide cell behavior, researchers at Case Western Reserve University report in the current issue of the journal, Acta Biomaterialia.

28 Aug 2012

XJB-5-131 prevents secondary damage of severe traumatic brain injury

Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.

27 Aug 2012

Abnormalities in mitochondrial length promote development of neurodegenerative diseases

Goldilocks was on to something when she preferred everything "just right." Harvard Medical School researchers have found that when it comes to the length of mitochondria, the power-producing organelles, applying the fairy tale's mantra is crucial to the health of a cell. More specifically, abnormalities in mitochondrial length promote the development of neurodegenerative diseases such as Alzheimer's.

24 Aug 2012

RNA switches can better equip and regulate viruses for many therapeutic applications

Numerous viruses are used in the service of science today. They serve as gene taxis to transfer therapeutic genes into body cells or as therapeutic viruses targeted to infect and destroy cancer cells. For such applications, the viruses are often equipped with additional genes, such as for immune mediators or for proteins inducing programmed cell death. However, these gene products can harm the body if they are released at the wrong moment or at excessive levels.

22 Aug 2012

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

Study identifies mode of death of cone photoreceptor cells in animal model of RP

Research conducted at the Angiogenesis Laboratory at Massachusetts Eye and Ear Infirmary, has for the first time, identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigmentosa (RP).

21 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Resveratrol might help improve mobility and prevent life-threatening falls among older people

In a stride toward better health in later life, scientists reported today that resveratrol, the so-called "miracle molecule" found in red wine, might help improve mobility and prevent life-threatening falls among older people.

20 Aug 2012

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.

18 Aug 2012

Combination of exercise and S-nitrosoglutathione improves recovery from stroke

In a study published in the current issue of Restorative Neurology and Neuroscience scientists report that a therapy combining exercise with the neurovascular protective agent S-nitrosoglutathione (GSNO) improved recovery from stroke in a rat model. GSNO is a compound found naturally in the body and it has no known side effects or toxicity.

16 Aug 2012

Combination of obatoclax and flavopiridol triggers multiple myeloma cell death

Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common form of blood cancer.

15 Aug 2012

Cell Death News and Research

Absence of Puma and Bim protein leads to autoimmune diseases

New cell screening method can identify potential anti-influenza drugs

Sorafenib could be effective against multiple myeloma

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

Glaucoma and cell death: an interview with Dr. Vivek Gupta

CNIO team generates transgenic mouse model for aplastic anaemia associated with short telomeres

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Study shows molecular mechanism behind type 3c pancreatic diabetes

Control of siRNA could aid regenerative medicine, cancer therapy

XJB-5-131 prevents secondary damage of severe traumatic brain injury

Abnormalities in mitochondrial length promote development of neurodegenerative diseases

RNA switches can better equip and regulate viruses for many therapeutic applications

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

Study identifies mode of death of cone photoreceptor cells in animal model of RP

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Resveratrol might help improve mobility and prevent life-threatening falls among older people

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

Combination of exercise and S-nitrosoglutathione improves recovery from stroke

Combination of obatoclax and flavopiridol triggers multiple myeloma cell death

Event Guide: 3rd Annual TRP Supply Chain & Manufacturing Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics